| Trial ID: | L0813 |
| Source ID: | RBR-8dp876
|
| Associated Drug: |
Silybum marianum
|
| Title: |
Epigenetic modulation by N-3 Polyunsaturated Fatty Acids and bioactive compounds (Silybum Marianum L) in Non-Alcoholic Fatty Liver Disease
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic Fatty Liver Disease;C06.552.241.519
|
| Interventions: |
Group I (SOP I): 30 patients will receive 3 capsules containing 1g of fish oil with 420 mg of EPA and 220 mg of DHA each once a day during the 12-month period.<br>Group II (SOP II): 30 patients will receive 3 capsules containing 1g of fish oil with 100 mg
|
| Outcome Measures: |
Regression of NAFLD by decreasing the expression of miRNAs related to this liver, quantified by real-time PCR at baseline and after 180 days of supplementation with fish oil rich in n-3 PUFA and Milk Thistle (Silybum marianum L.), from the observation of a variation of at least 5% in the pre- and post-intervention measurements.Increased n-3 polyunsaturated fatty acids in the plasma evaluated by gas chromatography, from the observation of a variation of at least 5% in the pre and post intervention measurements.
|
| Sponsor/Collaborators: |
Universidade Federal do Rio de Janeiro
|
| Gender: |
--
|
| Age: |
nannan
|
| Phases: |
Not applicable
|
| Enrollment: |
--
|
| Study Type: |
Intervention
|
| Study Designs: |
Clinical trial of treatment, randomized-controlled, double-blind, parallel and with four arms.
|
| Start Date: |
19/09/2017
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
7 February 2022
|
| Locations: |
Brazil
|
| URL: |
http://ensaiosclinicos.gov.br/rg/RBR-8dp876
|
